Omega-3 Petition Seeks Unqualified Blood Pressure, CHD Claims
This article was originally published in The Tan Sheet
Executive Summary
The trade group Global Organization for EPA and DHA Omega-3 petitions FDA for an unqualified health claim related to reduced blood pressure as a surrogate marker for coronary heart disease risk.
You may also be interested in...
FDA Status Updates On Citizen Petitions Would Not Signal Decision Pending
The agency's website soon could include petitions' status in the process, potentially providing some solace to affected sponsors. FDA dockets management staff members are preparing to add live status updates and a listing of all pending citizen petitions to the website.
Amarin Decision Could Spur Pressure Against FDA On Supplement Claim Policy
First Amendment advocate Jonathan Emord says the industry bows to FDA “intimidation” in not making truthful claims for their products. But the federal district court ruling for Amarin is the latest decision to strike against FDA’s policy on regulating supplement label claims, he says.
Amarin Decision Could Spur Pressure Against FDA On Supplement Claim Policy
First Amendment advocate Jonathan Emord says the industry bows to FDA “intimidation” in not making truthful claims for their products. But the federal district court ruling for Amarin is the latest decision to strike against FDA’s policy on regulating supplement label claims, he says.